Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017


Delayed Quote. Delayed Swiss Exchange - 01/25 01:11:48 pm
607 CHF   -0.88%
01:14aLonza's full-year core EBITDA up 20.7% on vaccine demand
01:06aLONZA : Full-Year Alternative Performance Measures Report
01:06aLONZA : Full-Year Results Report
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza : to Expand Microbial Development Laboratories

11/16/2021 | 08:07am EST
  • Lonza to expand development laboratories at the Visp (CH) site by 50% as part of Lonza's continued focus on expanding the microbial service offering supporting clinical and commercial programs
  • The expansion will consolidate upstream and downstream development teams with process analytics to promote efficiencies for project execution
  • Expanded development services will be available in Q4 2021

Basel, Switzerland, 16 November 2021 - Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced it has invested in additional microbial development capabilities in Switzerland. The investment will support increased capacity of development services targeting microbial-derived proteins with expanded laboratory space and equipment to be in use by the end of 2021.

The current extension will support new projects in Lonza's existing manufacturing assets as well as the previously announced mid-scale microbial capacity expansion. As microbial expression systems demand complex manufacturing processes, expanded development services will strengthen upstream, downstream and process analytics support for these new projects. Shiva Khalafpour, Vice President, Head of Microbial Business Unit, Lonza, commented:"The microbial-derived pipeline is growing at a healthy rate driven by an increase in alternatives to antibodies such as nanobodies, designed ankyrin repeat proteins (DARPins), single-chain antibodies, etc. For some of these molecules, microbial systems show better and more efficient productivities, which is increasing the trend toward outsourcing as customers need to rely on key microbial expertise. Expanding our development laboratories will enable us to support new customers with the development and manufacture of these molecules and other recombinant proteins for both clinical and commercial projects."

New development capacity will consolidate the microbial footprint at the Visp site and add new high throughput equipment and automation processes to drive efficiency and project delivery. The automation upgrades include three liquid handling workstations and other enabling equipment dedicated to upstream and downstream process development as well analytical method development. This high throughput capability will accelerate and enhance customer process data generation.

The expansion includes the installation of a dedicated pilot suite with a 50L fermenter and corresponding downstream equipment, which will generate non-GMP product suitable for formulation and toxicology studies. In addition, the pilot facility will enhance our internal technology transfer strategy and capability by providing a representative primary recovery scale.

The additional laboratory capacity will be aligned with available manufacturing capacity, including support of the new mid-scale assets, which will come online in 2022.

To learn more about Lonza's microbial fermentation capabilities, visit: pharma.lonza.com/offerings/microbial


Lonza Group Ltd. published this content on 16 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2021 13:06:06 UTC.

ę Publicnow 2021
All news about LONZA GROUP AG
01:14aLonza's full-year core EBITDA up 20.7% on vaccine demand
01:06aLONZA : Full-Year Alternative Performance Measures Report
01:06aLONZA : Full-Year Results Report
01:06aLONZA : Full-Year Results Presentation
01:03aLonza Delivers Strong 2021 performance with 20% CER Sales Growth
01/25Lonza Gets US Injunction in Patent Infringement Case Against Adva Biotechnology
01/25AlphaValue/Baader Europe Lowers Price Target on Lonza Group, Upgrades Recommendation to..
01/25LONZA : Obtains Order Preventing Infringement of Its Patents Covering the Cocoon« Platform
01/19LONZA : Drug Product Services Participates in the RealHOPE Project to Assess and Improve P..
01/18Lonza Signs Biologics Development Deal With Forbion, BioGeneration Ventures
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Sales 2021 5 187 M 5 652 M 5 652 M
Net income 2021 933 M 1 016 M 1 016 M
Net cash 2021 465 M 507 M 507 M
P/E ratio 2021 59,9x
Yield 2021 0,51%
Capitalization 45 090 M 49 060 M 49 134 M
EV / Sales 2021 8,60x
EV / Sales 2022 7,60x
Nbr of Employees 14 405
Free-Float -
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 607,00 CHF
Average target price 798,44 CHF
Spread / Average Target 31,5%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-20.30%49 060
MODERNA, INC.-38.07%63 777
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689
CELLTRION, INC.-19.95%19 358